抗心律失常药物治疗的最新进展
Arnela Saljic1,2, Jordi Heijman3, Dobromir Dobrev4,5,6,7
1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Drugs
|August 4, 2023
概括
新的抗心律失常药物 (AADs) 显示出对心律失常的管理有希望,尽管存在发展方面的挑战. 本综述探讨了新药,药物重新定位和改善药理疗法的未来方向.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 心律不整是死亡率和发病率的重要原因.
- 目前的抗心律失常药物 (AAD) 在有效性和安全性方面存在局限性.
- 新型ADS的开发由于各种挑战而放缓.
研究的目的:
- 审查新的抗不律性药物开发的概念性考虑.
- 总结临床开发中的药物用于心房的节律控制.
- 突出药物重用在心律失常管理中的潜力.
主要方法:
- 对抗心律失常药物开发和重新使用的文献综述.
- 对心房的临床试验中化合物的分析.
- 讨论抗不律性药理学的未来趋势.
主要成果:
- 一些有前途的新型抗不律性候选药物正在开发中.
- 药物重新定位和重新配方为心律失常治疗提供了可行的策略.
- 了解分子机制的进步指导了未来的AAD发展.
结论:
- 尽管面临挑战,但对改善的抗失常疗法存在谨慎乐观的前景.
- 新型药物和重新设计的药物具有更好的心律失常管理潜力.
- 对分子机制的持续研究对于推动AAD发展至关重要.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Dysrhythmias VI: Management of Dysrhythmias
19
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
770
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
770
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
875
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
875
Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622


